Mineralys Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor, initially for uncontrolled and resistant hypertension and potentially chronic kidney disease. The company had no approved products or product revenue. Its common stock began trading on Nasdaq under “MLYS” on February 9, 2023, after the reporting period.
Key Financial Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $26.3 million | $16.3 million | +$9.9 million |
| General and administrative expense | $5.2 million | $2.4 million | +$2.8 million |
| Total operating expenses | $31.5 million | $18.7 million | +$12.8 million |
| Other income, net | $1.7 million | $(0.7) million | +$2.4 million |
| Net loss | $29.8 million | $19.4 million | Loss increased $10.4 million |
| Net loss per share | $5.77 | $3.89 | Loss increased |
| Net cash used in operating activities | $29.2 million | $14.6 million | Cash use increased $14.7 million |
| Cash, cash equivalents and marketable securities | $110.1 million | $10.6 million | Significant increase |
| Accumulated deficit | $52.8 million | $23.0 million | Increased $29.8 million |
No meaningful profit margin can be calculated because the company had no revenue. The filing does not provide a clear adjusted EBITDA figure. No debt was outstanding at December 31, 2022; convertible notes had converted into preferred stock in February 2021.
Liquidity and Capital Resources
- Year-end cash and cash equivalents were $87.7 million, including $84.8 million in money market funds.
- Marketable securities were $22.4 million, consisting of short-term U.S. Treasury bills.
- Financing activities provided $128.0 million in 2022, primarily from $12.0 million of Series A preferred stock and $117.7 million of Series B preferred stock, net of issuance costs.
- Investing activities used $21.8 million, primarily reflecting purchases and maturities of marketable securities.
- Management stated that cash, cash equivalents and marketable securities, together with subsequent IPO proceeds, should fund operations for at least 12 months from the financial statement issuance date. The company expects continuing operating losses and will require additional capital to complete development and commercialization.
- Subsequent to year-end, the February 2023 IPO generated gross proceeds of $220.8 million and approximately $202.0 million of net proceeds. The preferred stock converted into 20.6 million common shares immediately before the IPO.
Clinical and Business Developments
- Mineralys completed the 200-subject Target-HTN Phase 2 trial in 2022. Lorundrostat produced placebo-adjusted reductions in systolic blood pressure of 9.6 mmHg at 50 mg once daily and 7.8 mmHg at 100 mg once daily, with reported statistical significance.
- Results indicated reductions in 24-hour, nighttime and central blood pressure, with stronger responses reported in obese patients and patients using diuretics.
- Safety findings included dose-dependent potassium increases, six isolated potassium readings above 6.0 mmol/L across active cohorts, reversible hypotension or orthostatic hypotension, and one serious hyponatremia event considered possibly related to treatment. No clinically relevant cortisol suppression was observed.
- In November 2022, the FDA end-of-Phase 2 meeting supported the proposed pivotal development approach, doses and clinical trial designs, according to management.
Guidance, Outlook and Material Risks
- Management planned to initiate the ADVANCE-HTN Phase 2 trial in the first half of 2023, with up to approximately 300 subjects and topline data expected in the first half of 2024.
- A hypertension Phase 3 trial with up to approximately 1,000 subjects was planned for the second half of 2023, with topline data expected in mid-2025.
- A Phase 2 trial in a chronic kidney disease population was planned for mid-2023, with topline data expected in the first half of 2024.
- These timelines are forward-looking plans, not guarantees. Lorundrostat has not completed a pivotal trial and has not received regulatory approval.
- The company depends substantially on the success of its single product candidate and expects materially higher research, development, regulatory, manufacturing and public-company costs.
- Key risks include clinical failure or delays, hyperkalemia and other adverse events, patient enrollment challenges, regulatory uncertainty, reliance on contract research organizations and manufacturers, lack of commercial manufacturing arrangements, competition from existing generic therapies and other drug candidates, and the need for additional financing.
- The Mitsubishi Tanabe license requires up to $9.0 million in development milestones, up to $155.0 million in commercial milestones, up to $10.0 million for a second indication, and tiered royalties generally ranging from the mid-single digits to 10% of net sales. Termination of the license could materially impair the business.
- The company reported no material legal proceedings. COVID-19, inflation, supply-chain disruptions, market volatility and geopolitical events could affect development timelines, costs and access to capital.
Material Changes Versus 2021
- Research and development expense increased 61%, primarily because of Target-HTN clinical costs, clinical supply and manufacturing costs, regulatory costs and additional personnel.
- General and administrative expense increased 116%, primarily from higher professional fees and personnel costs.
- Operating cash use approximately doubled as clinical development expanded.
- Liquidity improved substantially following $129.6 million of net preferred-stock financing in 2022 and investment of excess cash in Treasury securities.
- The company advanced lorundrostat from Phase 2 proof-of-concept development toward planned Phase 2 and Phase 3 programs.
- The February 2023 IPO materially changed the company’s capitalization and liquidity after year-end; those proceeds are not included in December 31, 2022 cash balances.
Most Important Facts to Verify
- Whether ADVANCE-HTN, the planned hypertension Phase 3 trial and the CKD trial started on schedule and whether enrollment and data-readout timelines changed.
- Whether later-stage trials reproduce the Target-HTN blood-pressure reductions and establish a favorable long-term potassium and renal safety profile.
- The company’s current cash burn, remaining runway after the IPO and timing of any future capital raises.
- Any FDA feedback, clinical holds, regulatory designations or changes to the anticipated NDA pathway.
- The status, scope and remaining term of patents and the company’s compliance with the Mitsubishi Tanabe license.
- Potential dilution from outstanding options, restricted stock, the 2023 incentive plan and employee stock purchase plan.
- The effect of competition from inexpensive generic antihypertensives, mineralocorticoid receptor antagonists and competing aldosterone synthase inhibitor programs.